UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):  May 23, 2013
Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
001-33137
14-1902018
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

2273 Research Boulevard, Suite 400, Rockville, Maryland
20850
(Address of Principal Executive Offices)
(Zip Code)

Registrant's telephone number, including area code:  (301) 795-1800
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
Item 5.07
Submission of Matters to a Vote of Security Holders.

Emergent BioSolutions Inc. held its 2013 Annual Meeting of Stockholders on May 23, 2013.  A total of 33,555,278 shares of the Company's common stock were present or represented by proxy at the meeting, which represented approximately 92.90% of the Company's 36,117,093 shares of common stock that were outstanding and entitled to vote at the meeting as of the record date of March 25, 2013. Stockholders considered the three proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement filed April 8, 2013.

Proposal 1. The election of Fuad El-Hibri and Ronald B. Richard to serve as Class I directors, each for a term of three years. Both director nominees were elected. The voting results were as follows:

Nominees
 
For
 
Withheld
 
 Broker Non-Votes
Fuad El-Hibri
 
             29,726,074
 
                     1,389,627
 
                            2,439,577
Ronald B. Richard
 
             30,793,374
 
                        322,327
 
                            2,439,577

Proposal 2. The ratification of the appointment by the audit committee of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2013. Proposal 2 was approved. The voting results were as follows:

For
   
Against
   
Abstaining
 
 
33,298,102
     
89,042
     
168,134
 

Proposal 3. An advisory vote to approve the compensation of the Company's named executive officers. Proposal 3 was approved. The voting results were as follows:

For
   
Against
   
Abstaining
   
Broker Non-Votes
 
 
30,889,842
     
57,591
     
168,267
     
2,439,578
 






SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  May 23, 2013
EMERGENT BIOSOLUTIONS INC.
 
By:
/s/Jay G. Reilly
Jay G. Reilly
General Counsel